Golidocitinib vs placebo for PTCL maintenance after first chemo
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a daily pill called golidocitinib can keep your PTCL from coming back after you've had a good response to your first chemotherapy. The study compares the drug to a placebo (a pill with no active medicine) to see if it helps prevent relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with a specific type of peripheral T-cell lymphoma (PTCL) and are in remission or had a good response to your first chemotherapy.
- You are either over 65 or, if 65 or younger, you have decided not to have a stem cell transplant.
- You have not used a JAK or STAT3 inhibitor drug before.
- You do not have active infections like tuberculosis, HIV, or hepatitis B or C.
- Your heart, lungs, kidneys, liver, and blood counts are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.